OR WAIT null SECS
© 2023 MJH Life Sciences™ and Diagnostic Imaging. All rights reserved.
ScreenPoint Medical receives greenlight for Transpara™ 1.6.0. to reduce read times.
ScreenPoint Medical received clearance Monday from the U.S. Food & Drug Administration (FDA) for the first artificial-intelligence solution functional for both 2D and 3D mammography.
The greenlight for the solution, Transpara™ 1.6.0, expands ScreenPoint’s existing global marekt for Transpara 3D technology.
“This is a major breakthrough from ScreenPoint Medical, and it means that our new and existing U.S. customers now have access to the power of Transpara 3D for the first time,” ScreenPoint Chief Executive Officer Nico Karssemeijer said in a statement. “Multiple independent peer-reviewed publications have already demonstrated that Transpara significantly improves accuracy in 2D mammography, now the same applies for 3D.”
The company earned FDA clearance by demonstrating, through a clinical reader study, that radiologist accuracy improved when they read 3D mammograms while using Transpara. Additionally, according to study results, their reading time fell to approximately 35 seconds, roughly the same as the time needed for reading 2D mammograms.
Alongside reduced turn-around time, ScreenPoint officials also said the Transpara™ 1.6.0. interface was re-designed, using the company’s patented co-registration slice technology, to, potentially, maximize reading workflow.
Based on company information, Transpara has clinical installations in 15 countries, and it will be marketed in the United States by ScreenPoint Medical Inc., Siemens Healthineers USA, and Volpara Solutions.